Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Vatelizumab: Difference between pages
(Difference between pages)
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 460519712 of page Vatelizumab for the Chem/Drugbox validation project (updated: 'CAS_number'). |
m Task 18 (cosmetic): eval 2 templates: del empty params (3×); |
||
| Line 1: | Line 1: | ||
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Vatelizumab|oldid=460519712}} 460519712] of page [[Vatelizumab]] with values updated to verified values.}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| verifiedrevid = |
| verifiedrevid = 470629425 |
||
| type = mab |
| type = mab |
||
| image = |
| image = |
||
| Line 9: | Line 8: | ||
| source = zu |
| source = zu |
||
| target = [[integrin alpha 2]] |
| target = [[integrin alpha 2]] |
||
<!--Clinical data--> |
<!--Clinical data --> |
||
| tradename = |
| tradename = |
||
| Drugs.com = |
| Drugs.com = |
||
| Line 16: | Line 15: | ||
| pregnancy_US = <!-- A / B / C / D / X --> |
| pregnancy_US = <!-- A / B / C / D / X --> |
||
| pregnancy_category= |
| pregnancy_category= |
||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
||
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
||
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
||
| Line 22: | Line 21: | ||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
| ⚫ | |||
| ⚫ | |||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| Line 29: | Line 27: | ||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
| ⚫ | |||
| ⚫ | |||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = none |
||
| CAS_number_Ref = {{cascite| |
| CAS_number_Ref = {{cascite|changed|??}} |
||
| CAS_number |
| CAS_number = 1238217-55-4 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = A4R7G50030 |
|||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| Line 40: | Line 39: | ||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = |
||
| ⚫ | |||
| ⚫ | |||
| chemical_formula = |
| chemical_formula = |
||
| molecular_weight = |
| molecular_weight = |
||
}} |
}} |
||
'''Vatelizumab''' is an [[immunomodulator]]. It binds to [[integrin alpha 2]].<ref>{{cite journal|author=[[World Health Organization]]|year=2011|title=International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105|url=https://www.who.int/medicines/publications/druginformation/innlists/INNprepub105.pdf|journal=WHO Drug Information|volume=25|issue=2}}</ref> |
|||
It was withdrawn from Phase II trials for [[inflammatory bowel disease]] due to a lack of efficacy.<ref>{{cite journal |vauthors=Mozaffari S, Nikfar S, Abdollahi M |title=Inflammatory bowel disease therapies discontinued between 2009 and 2014 |journal=Expert Opin Investig Drugs |volume=24 |issue=7 |pages=949–56 |date=2015 |pmid=25861835 |doi=10.1517/13543784.2015.1035432 |s2cid=26104155 }}</ref> |
|||
== References == |
|||
<references/> |
|||
{{monoclonals for immune system}} |
|||
[[Category:Monoclonal antibodies]] |
|||
[[Category:Abandoned drugs]] |
|||
{{monoclonal-antibody-stub}} |
|||
{{antineoplastic-drug-stub}} |
|||